Form record received

International Workshop on Waldenstrom's Macroglobulinemia <pattersonkent@outlook.com>
Mon 7/15/2024 11:23 AM
To:Patterson, Christopher <Christopher_Patterson@DFCI.HARVARD.EDU>

External Email - Use Caution

Record saved to database with ID: 130

Form ID: 1
Form title: Abstract Submission
Form name: Abstract_Submission
Submitted at: 2024-07-15 11:21:50
Submitter IP: 82.36.103.192
User-ID: 0
Username: -
User full name: -
Submitter provider: Unknown
Submitter browser: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_15_7) AppleWebKit/605.1.15 (KHTML, like Gecko) Version/16.6 Safari/605.1.15
Submitter operating system: mac

First Name: Oliver
Last Name: Tomkins
Email: oliver.tomkins@nhs.net
Phone Number (optional): +447858377077
Registration Type: Delegate in Training
Abstract Title: Bing-Neel Syndrome – A Case Series of 46 Patients from the United Kingdom
Select abstract file to attach:
/home/dkwolfpk2016/public_html/waldenstromsworkshop/media/breezingforms/uploads/bingneeliwwm12final.docx
Please consider me for a YIA grant: YIA Grant Consideration
Conference: IWWM12

Bing-Neel Syndrome – A Case Series of 46 Patients from the United Kingdom

Oliver Tomkins[1], Jahanzaib Khawaja[1], Nicole Japzon[1], Chandra Hoskote[2], Jindriska Lindsay[1], Charalampia Kyriakou[1], Michael P Lunn[2], Shirley D'Sa[1]

1. UCLH Centre for WM and Related Conditions, University College London Hospitals NHS Foundation Trust, London, United Kingdom
2. Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, United Kingdom

Background

Central nervous system involvement with Waldenstrom's Macroglobulinaemia (WM) or lymphoplasmacytic lymphoma (LPL) is termed Bing-Neel syndrome (BNS). An infrequent complication, it nevertheless causes significant morbidity. Optimum treatment sequencing remains to be established, with traditional CNS-penetrating chemotherapy agents and novel Bruton's Tyrosine Kinase inhibitors (BTKis) employed. We describe features and treatment outcomes at our WM centre.

Methods

A retrospective cohort analysis was undertaken using the UCLH WM patient registry.

Results

BNS was diagnosed in 59 patients between years 2012 and 2024; 46 had adequate data. Median follow up was 50 months (1-150m). Table 1 lists clinicopathological characteristics. Median duration from BNS symptom onset to diagnosis 5m (range 0-60m).

A preceding diagnosis of WM/LPL was present in 34/46 (73.9%) (WM in 31, IgG LPL 2, IgA LPL 1). Median time from WM diagnosis to BNS was 55m (0-265m). BNS occurred as part of systemic progression in 15 and CNS-only in 19. No prior history of WM/LPL in 12/46 (26.1%) cases; a systemic condition was established in 8 (5 LPL, 3 IgM MGUS) whereas isolated BNS occurred in 4 patients.

Diagnosis was made using brain biopsy in 2 and CSF studies in 44 (cytology 1, immunophenotyping 27, PCR 16). CSF $MYD88^{L265P}$ detected in 29/30 patients; 3 others had IgH rearrangements detected. Lack of surface immunoglobulin expression in 16 patients, but with PCR-proven clonality.

Prior treatment for WM had been given in 21/46 patients, median 1 prior line (range 0-4). Frontline (1L) therapy for BNS administered in 42/46 (95.6%), with high-dose methotrexate (MTX)-based regimens in 37 and BTKi in 5 (table 2). BCNU/Thiotepa autologous stem cell transplant (ASCT) consolidation in 3. Intrathecal-only chemotherapy was given in 2. Median post-treatment CSF WCC 4 (0-297) and protein 0.78 (0.34-6.03). Median 1L overall survival (OS) was not reached, 1- and 3-year rates 93% (84-100%).

Median 1L PFS 49m (26-63m), with 1-, 3-year and 5-year PFS 87% (76-100%), 56% (40-78%) and 30% (16-55%). Attainment of frontline negative CSF PCR for $MYD88^{L265}$ and/or IgH PCR occurred in 13/16 evaluable patients; none subsequently relapsed. Residual disease following MTX-based therapy present in 15/37 (40.6%), who initiated BTKi consolidation. PFS following 1L MTX-based therapy only 81.3% (64.2-100) at 1 year and 49.9% (29-85.7%) at 3 years; MTX-based therapy followed by BTKi consolidation 100% at 1- and 3 years; and BTKi-only therapy 100% at 1 year.

2L therapy was given in 23/46 (50%) patients, 21 with BTKi and 2 with chemoimmunotherapy. Median PFS following 2nd line BTKi therapy not reached, with 1- and 3-year PFS 89% (79-100%). Attainment of 2L CSF negativity by MYD88 or IgH PCR occurred in 6/9 evaluable patients, all on BTKis; none subsequently relapsed. 3L therapy was given in 3 patients.

Conclusion

Symptoms of BNS are heterogenous. A quarter of patients have no history of LPL/WM when presenting with BNS. Over ½ cases with known WM occur as CNS-only progression. Isolated BNS is rarely seen. Patients who attained CSF $MYD88^{L265}$ or IgH PCR-negativity did not subsequently relapse from BNS. Regimens incorporating BTKi-based therapy result in excellent PFS rates.

Table 1 – Clinicopathological Characteristics of Patients with Bing-Neel Syndrome	
Demographics	n = 46
Age, median (range)	66.5 (48-85)
Male	26 (52.5%)
WM Disease Characteristics	
Extramedullary disease	14/46 (30.4%)
Bone marrow infiltration, median (range)	20% (0-80%)
Bone marrow $MYD88^{L265}$	27/28 (96.4%)
Bone marrow $CXCR4^{WHIM}$	1/6 (16.7%)
Symptoms	
Sensory and/or motor deficits	21 (45.7%)
Cognitive change or confusion	8 (17.4%)
Cranial nerve	5 (10.9%)
Headaches	4 (8.7%)
Seizures	3 (6.5%)
Hearing loss	3 (6.5%)
Ocular/orbital	2 (4.3%)
CSF Findings	
CSF leucocyte count, median (range)	15.5 (1-153)
CSF protein, median (range)	1.40 (0.25-4.69)
CSF IgM, median (range)	4.13 (0.147-475)
CSF $MYD88^{L265P}$	29/30 (96.7%)
Imaging Findings	
Parenchymal lesions	12 (26.1%)
Leptomeningeal enhancement	33 (71.7%)
Intracranial	24 (52.2%)
Spinal/cauda equina	27 (58.7%)
No findings	7 (15.2%)

Table 2 – Bing-Neel Syndrome Treatment Regimens	
Frontline (1L) Treatment Regimen	n = 44/46 (95.7%)
Rituximab-Cytarabine-MTX	16 (36.4%)
MATRix (MTX-Cytarabine-Thiotepa-Rituximab)	15 (34.1%)
R-IDARAM (Rituximab-MTX-Cytarabine-Idarubicin)	5 (11.4%)
R-ESHAP/MTX(Rituximab-Etoposide-Methylprednisolone-Cytarabine-Cisplatin)	1 (2.3%)
Zanubrutinib	4
Ibrutinib	1
MTX Intrathecal	1
MTX/Cytarabine/Hydrocortisone Intrathecal	1
+BCNU/Thiotepa ASCT consolidation	3
+BTKi consolidation	15
Second Line (2L) Treatment Regimen	n = 23/46 (50%)
Ibrutinib	15 (65.2%)
Zanubrutinib	6 (26.1%)
R-Bendamustine	1 (4.3%)
R-Cladribine	1 (4.3%)
Third Line (3L) Treatment Regimens	n= 3/46 (6.5%)
MATRix+ASCT	1
R-ICE +ASCT	1
R-Bendamustine	1

1L OS All Therapy



1L PFS All Therapy



1L PFS MTX-Chemo vs BTKi vs BTKi consolidation



2L BTKi PFS